BALTIMORE, Md., Nov. 20 /PRNewswire/ -- Alba Therapeutics Corporation announced today that Blake Paterson, M.D., the company’s Chief Executive Officer, will present at the 18th Annual Piper Jaffray Healthcare Conference on Friday, December 1, 2006 at 9:10 a.m. eastern time.
The conference is being held at the Pierre Hotel in New York City from November 29th to December 1st.
About Alba: Alba Therapeutics is a biopharmaceutical company dedicated to discovering, developing and commercializing superior immunological disease and inflammation therapeutics by leveraging our barrier function technology platform delivering value to our patients, employees and shareholders. Alba’s platform, the zonulin pathway, provides the ability to transiently and physiologically regulate tight junctions in cellular barriers such as the intestinal mucosa and the pulmonary epithelia. Modulation of paracellular permeability allows Alba to develop applications ranging from therapies associated with tight junction dysfunction and autoimmunity to vaccine and drug delivery. Alba’s lead product, AT-1001, a zonulin receptor antagonist, is currently in a Phase II trial for Celiac Disease. Alba is testing AT-1001 and other antagonists in a variety of autoimmune and inflammatory diseases and expects to enter clinical trials in additional indications during 2007.
Contact: Stuart Sedlack, SVP, Corporate Development Phone: 410-319-0780 E-mail: info@albatherapeutics.com Web sites: http://www.albatherapeutics.com
Alba Therapeutics Corporation
CONTACT: Stuart Sedlack, SVP, Corporate Development of Alba TherapeuticsCorporation, +1-410-319-0780, info@albatherapeutics.com
Web site: http://www.albatherapeutics.com/
